索拉非尼治疗肝细胞肝癌耐药的逆转机制研究进展  

Research progress on reversal of drug resistance to Sorafenib in primary liver cancer

作　　者：况芳圆 邵初晓 陈枫峰 涂朝勇[3] Kuang Fangyuan;Shao Chuxiao;Chen Fengfeng;Tu Chaoyong(School of Medicine,Shaoxing University,Shaoxing 312000,China;Department of Hepatobiliary and Pancreatic Surgery,Lishui People's Hospital,Lishui 323000,China;Department of Hepatobiliary and Pancreatic Surgery,Lishui Central Hospital,Lishui 323000,China)

机构地区：[1]绍兴文理学院医学院,绍兴312000 [2]丽水市人民医院肝胆胰外科,丽水323000 [3]丽水市中心医院肝胆胰外科,丽水323000

出　　处：《国际外科学杂志》2023年第4期279-284,共6页International Journal of Surgery

基　　金：丽水市重点研发计划项目(2022ZDYF08)。

摘　　要：肝细胞肝癌(HCC)是一种在全球范围内发病率高、死亡率高的恶性肿瘤,由于起病隐匿,患者首次确诊时大都不适合接受根治性治疗。而系统治疗作为HCC治疗的重要方案之一,最具有代表性的药物之一就是索拉非尼,其对不同分期的HCC患者均有一定的生存获益。但由于HCC对索拉非尼易产生耐药性,极大地限制了其疗效。目前为止,人们已经发现了一些天然物质、实验药剂和生物大分子通过肿瘤细胞微环境、代谢等方面机制来逆转HCC对索拉非尼的耐药性。本文将总结上述物质与其发生机制,以期为完善索拉非尼的治疗方案,为患者治疗提供研究思路。Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence rate and mortality worldwide. However, most patients are not suitable for radical treatment at the time of first diagnosis. As one of the important schemes for the treatment of HCC, one of the most representative drug is Sorafenib, which has certain survival benefits for HCC patients at different stages. However, the drug resistance of HCC to Sorafenib greatly limits its efficacy. So far, people have found that some natural substances, experimental agents and biological macromolecules can reverse the drug resistance of HCC to Sorafenib through tumor cell microenvironment, metabolism and other mechanisms. This article will summarize the above substances and their mechanism in order to provide research ideas for the improvement of Sorafenib′s treatment program.

关 键 词：肝肿瘤 癌 肝细胞 逆转录作用 索拉非尼 耐药性 

分 类 号：R735.7[医药卫生—肿瘤]